VEGF and PEDF in Patients With Myopic Choroidal Neovascularization

Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02175940

Enrollment

Registered

2014-06-26

Start date

2013-07-31

Completion date

2014-05-31

Last updated

2014-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopic Choroidal Neovascularization, PEDF Aqueous Level, VEGF Aqueous Level

Brief summary

This was a prospective, case-control study investigating aqueous levels of VEGF and PEDF in eyes with mCNV treated with IVB.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* pathologic myopia, defined as spherical equivalent \>6 diopters and axial length \>26 mm * posterior pole myopic retinal changes (posterior staphyloma, chorioretinal atrophy, papillary crescent); * fluorescein angiography, indocyanine green angiography and optical coherence tomography detection of the subfoveal or juxtafoveal choroidal neovascularization * clear ocular media;

Exclusion criteria

* previous treatment for choroidal neovascularization, including the previous intravitreal drug injection or PDT * presence of other maculopathy as diabetic retinopathy or retinal vascular occlusion * history of recent myocardial infarction or other thromboembolic events * ongoing uncontrolled hypertension or glaucoma * refractive media opacities * previous eye surgery

Design outcomes

Primary

Measure	Time frame	Description
vascular endothelial growth factor (VEGF) aqueous levels	2 months	VEGF aqueous levels before and after intravitreal ranibizumab
pigment epithelium-derived factor (PEDF) aqueous levels	2 months	PEDF aqueous levels before and after intravitreal ranibizumab

Secondary

Measure	Time frame
best-corrected visual acuity	2 months
central retinal thickness	2 months

Countries

Italy

Outcome results